Ligand Pharmaceuticals Inc.
LGND Nasdaq
SEC CIK 886163
Follow Ligand Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$78.7M
−31.8% vs same quarter last year
Net income
−$28.5M
−124.3% vs same quarter last year
EPS, diluted
−$1.43
−125.2% vs same quarter last year
Operating cash flow
−$27.6M
−310.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $268.1M | $124.5M |
| FY24 | $167.1M | −$4M |
| FY23 | $131.3M | $52.2M |
| FY22 | $196.2M | −$33.4M |
| FY21 | $241.5M | $57.1M |
| FY20 | $163.6M | −$3M |
| FY19 | $120.3M | $629.3M |
| FY18 | $251.5M | $143.3M |
| FY17 | $141.1M | $12.6M |
| FY16 | $109M | −$1.6M |
| FY15 | $71.9M | $229.8M |
| FY14 | $64.5M | $12M |
| FY13 | $49M | $11.4M |
| FY12 | $31.4M | −$527K |
| FY11 | $30M | $9.7M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | 15.3% | 46.4% |
| FY24 | - | −13.5% | −2.4% |
| FY23 | - | 9.1% | 39.7% |
| FY22 | - | 1.5% | −17% |
| FY21 | - | 43% | 23.7% |
| FY20 | - | 22.9% | −1.8% |
| FY19 | - | 671% | 523.2% |
| FY18 | 97.5% | 65.1% | 57% |
| FY17 | 96.2% | 48.2% | 8.9% |
| FY16 | 94.9% | 40.3% | −1.5% |
| FY15 | 91.9% | 38% | 319.6% |
| FY14 | 85.8% | 30.4% | 18.6% |
| FY13 | 88.3% | 30.5% | 23.3% |
| FY12 | 88.5% | 0.6% | −1.7% |
| FY11 | 83.7% | −2.9% | 32.3% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $48.9M |
| FY24 | $95.2M |
| FY23 | $46.1M |
| FY22 | $119.9M |
| FY21 | $70M |
| FY20 | $50.1M |
| FY19 | −$31.9M |
| FY18 | $193.2M |
| FY17 | $86.4M |
| FY16 | $58.9M |
| FY15 | $41.6M |
| FY14 | $20.6M |
| FY13 | $20.3M |
| FY12 | −$434K |
| FY11 | −$1.3M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $15M |
| FY24 | $0 |
| FY23 | $0 |
| FY22 | $0 |
| FY21 | $0 |
| FY20 | $78M |
| FY19 | $453M |
| FY18 | $122.9M |
| FY17 | $2M |
| FY16 | $3.9M |
| FY15 | $489K |
| FY14 | $68M |
| FY13 | $0 |
| FY12 | $0 |
| FY11 | $55K |
- Ligand Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Ligand Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | 46.4% | −30.6% |
| FY24 | −2.4% | −47% |
| FY23 | 39.7% | −58% |
| FY22 | −17% | −80.4% |
| FY21 | 23.7% | −71.8% |
| FY20 | −1.8% | −62.2% |
| FY19 | 523.2% | −46.2% |
| FY18 | 57% | −49.6% |
| FY17 | 8.9% | −45.9% |
| FY16 | −1.5% | −36% |
| FY15 | 319.6% | −37.8% |
| FY14 | 18.6% | −35.5% |
| FY13 | 23.3% | −37.1% |
| FY12 | −1.7% | −29.1% |
| FY11 | 32.3% | −27.9% |